NCT04122833
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study No drug interventions Not Available Not Available recruiting NCT04148898
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis treatment 2 unknown_status NCT04636593
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC treatment 2 unknown_status NCT03647956
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors treatment 2 unknown_status NCT05778149
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation treatment 2 not_yet_recruiting NCT05244213
Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC treatment 2 active_not_recruiting NCT05146219
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation No drug interventions treatment 2 active_not_recruiting NCT06363734
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial treatment 2 recruiting NCT04989322
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC treatment 2 recruiting NCT05241873
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations treatment 1 / 2 active_not_recruiting NCT04768491
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC Not Available Not Available recruiting NCT04862780
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC treatment 1 / 2 active_not_recruiting NCT02846792
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer treatment 1 / 2 terminated NCT05136014
Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model No drug interventions Not Available Not Available unknown_status NCT05258279
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations treatment 2 active_not_recruiting NCT05382728
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) treatment 3 recruiting NCT06053099
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) No drug interventions diagnostic Not Available recruiting NCT05948813
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases treatment 2 recruiting NCT02299765
Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC treatment 4 terminated NCT04470076
Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation treatment 2 unknown_status NCT05257967
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease No drug interventions diagnostic Not Available recruiting NCT04944069
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis treatment Not Available not_yet_recruiting NCT04425681
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer treatment 2 unknown_status NCT04764214
SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs treatment 2 completed NCT03544814
EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression treatment 2 completed NCT05153408
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC treatment 1 terminated NCT02949843
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations treatment 2 terminated NCT05768490
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases treatment 3 recruiting NCT04233021
Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation treatment 2 active_not_recruiting NCT01941654
ATOM_local Ablative Therapy No drug interventions treatment 2 completed NCT02326285
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB treatment 2 / 3 terminated